Have a feature idea you'd love to see implemented?
Let us know!
ANIX Anixa Biosciences Inc
Price (delayed)
$2.8
Market cap
$90.15M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.39
Enterprise value
$89.11M
Anixa Biosciences Inc. is a biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa's therapeutics portfolio includes a cancer immunotherapy program which uses a novel type
Highlights
The debt has increased by 33% YoY but it has decreased by 2.1% from the previous quarter
The gross profit has dropped by 100% year-on-year
The company's revenue has shrunk by 100% YoY
Key stats
What are the main financial stats of ANIX
Market
Valuations
Earnings
Shares outstanding
32.2M
Market cap
$90.15M
Enterprise value
$89.11M
Price to earnings (P/E)
N/A
Price to book (P/B)
4.51
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Net income
-$12.55M
EBIT
-$12.55M
EBITDA
-$12.52M
Free cash flow
-$7.34M
Per share
Balance sheet
Liquidity
EPS
-$0.39
EPS diluted
-$0.39
Free cash flow per share
-$0.23
Book value per share
$0.62
Revenue per share
$0
TBVPS
$0.68
Total assets
$21.59M
Total liabilities
$2.7M
Debt
$232,000
Equity
$20M
Working capital
$18.86M
Debt to equity
0.01
Current ratio
8.54
Quick ratio
8.04
Net debt/EBITDA
0.08
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-53.3%
Return on equity
-55.8%
Return on invested capital
-60.7%
Return on capital employed
-65.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ANIX stock price
How has the Anixa Biosciences stock price performed over time
Intraday
-0.36%
1 week
22.81%
1 month
4.09%
1 year
-42.27%
YTD
20.69%
QTD
20.69%
Financial performance
How have Anixa Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$13.83M
Net income
-$12.55M
Gross margin
N/A
Net margin
N/A
The gross profit has dropped by 100% year-on-year
The company's revenue has shrunk by 100% YoY
The net income has declined by 28% year-on-year
ANIX's operating income is down by 26% year-on-year
Growth
What is Anixa Biosciences's growth rate over time
Valuation
What is Anixa Biosciences stock price valuation
P/E
N/A
P/B
4.51
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ANIX's EPS is down by 22% year-on-year
The equity has contracted by 18% YoY and by 8% from the previous quarter
The price to book (P/B) is 15% lower than the 5-year quarterly average of 5.3 and 11% lower than the last 4 quarters average of 5.1
The company's revenue has shrunk by 100% YoY
Efficiency
How efficient is Anixa Biosciences business performance
The return on equity has declined by 48% year-on-year and by 6% since the previous quarter
The company's return on assets fell by 47% YoY and by 6% QoQ
Anixa Biosciences's return on invested capital has decreased by 28% YoY and by 7% QoQ
Dividends
What is ANIX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ANIX.
Financial health
How did Anixa Biosciences financials performed over time
The current ratio has declined by 32% year-on-year and by 24% since the previous quarter
The company's quick ratio fell by 32% YoY and by 24% QoQ
The debt is 99% less than the equity
The debt has increased by 33% YoY but it has decreased by 2.1% from the previous quarter
The equity has contracted by 18% YoY and by 8% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.